1 / 2

Acute Lymphoblastic Leukemia

Get to Know About the Molecular Cytogenetic Analysis for Acute Lymphoblastic Leukemia. This test will diagnose and monitor the treatment response of patients.

kmathewriya
Télécharger la présentation

Acute Lymphoblastic Leukemia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cytogenetics Molecular Cytogenetic Analysis for Acute Lymphoblastic Leukemia Test Purpose : To diagnose and monitor the treatment response of patients with B-cell acute lymphoblastic leukemia (B-ALL). Methodology : Fluorescence In Situ Hybridization (FISH). Testing Procedure : This test includes culture of blood / bone marrow cells, followed by analysis of special sites of the chromosome using fluorescent probes. Gene Analyzed Turn Around Time : BCR-ABL1, t(9:22)(q34;q11). : 4 working days. Specimen Type : Bone marrow (Preferably)/ Peripheral blood. Specimen Volume Collection instructions : 3-4 ml bone marrow / 4 ml blood in green top heparin tube. : Label the vacutainer with patient’s name and specimen type. Specimen Transport : The specimen should be shipped at 18-25°C, do not freeze. It should reach the lab within 24 hours of collection (preferably at the earliest). In case of delay, sample to be stored on the door shelf of the refrigerator. Mandatory Requirements Complete blood count and bone marrow/ peripheral blood blast percentage must be provided. Specify detailed clinical history, collection date & time of sample withdrawn on test request form*. : Significance of Gene tested : BCR-ABL1, t(9:22)(q34;q11) ¤ Present in 25% adult B-ALL and 2-4% Pediatric B-ALL cases. ¤ Results in chimeric fusion protein with constitutive tyrosine kinase activity. ¤ Presence of BCR-ABL1 fusion gene confers a poor prognosis.

  2. Highlights of the Test: ¤ Identification of specific BCR-ABL1 gene rearrangement is critical for disease evaluation, optimal risk stratification and treatment planning. ¤ BCR-ABL1 fusion gene amplification status, one of the prime factors for drug resistance and adverse prognosis in ALL, is also evaluated by this assay. ¤ This test is able to identify masked and variant Ph (Philadelphia Chromosome) translocations which are not detected by conventional cytogenetics and PCR primers. ¤ A single FISH assay can cover all the splice variants of BCR-ABL1 fusion gene including b2a2 or b3a2 coding for p210; e1a2 coding for p190; e19a2 (c3a2) coding for p230. ¤ Sensitivity and Accuracy: For initial diagnosis, 100-200 interphase nuclei are counted. For therapeutic response analysis, with a previously abnormal result, up to 500 interphase nuclei may be counted. ¤ CE-IVD approved LSI BCR/ABL1 dual color, dual fusion translocation probe kit is used for the assay. Note: A repeat sample may be needed in case of culture failure. If further testing is required, additional charges may be incurred. *Samples shall be rejected if above details are not provided. Corporate Office & Referral Laboratory, DDRC SRL Towers, Panampilly Nagar, Kochi-682 036 Ph: +91 484 2318222, 2318223 email: info@ddrcsrl.com www.ddrconline.com, www.ddrclab.com 94977 17850 94977 17842

More Related